Observation on JPM 2026: Pressures, Transactions and Transformations
What Are Multinational Corporations (MNCs) Looking to Acquire in the New Year?
Time：
2026-01-15 08:20
Author：
xieyijun
PD-(L)1/VEGF Bispecific Antibodies: A Bright Future of the Chinese Narrative
Reshaping the Landscape of Tumor Immunotherapy
Time：
2026-01-14 08:45
Author：
xieyijun
Patent Hidden War: The Life-and-Death Game of Innovative Drugs
Time：
2026-01-13 09:26
Author：
xieyijun
Next Stop "Drug King"? The Hot and Cold Race of Dual Antibodies for Autoimmunity
Super BD (Business Development) Arena
Time：
2026-01-12 08:21
Author：
xieyijun
Stock Plummets 99.9%: An Ophthalmic Biotech’s Fight for Survival
The window of opportunity is closing.
Time：
2026-01-11 08:23
Author：
xieyijun
The first small nucleic acid company goes public.
RiboBio celebrates its IPO on the Hong Kong Stock Exchange.
Time：
2026-01-09 18:30
Author：
xieyijun
The "Spectacular Breakup" of ImmuneOnco Biopharma
Act decisively when the time comes.
Time：
2026-01-07 18:48
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务